TABLE 1.

Patient Characteristics and Information on Vaccination and COVID‐19 Outcomes Among Patients With CLD

Age (years)	Sex	Etiology	CLD Severity	Vaccine Type	Vaccine Doses	Weeks Between v1 & SARS‐CoV‐2	Weeks Between v2 & SARS‐CoV‐2	Hospitalized	Invasive Ventilation	ICU	Death
60‐69	M	HCV	CP‐A	Oxford‐AstraZeneca	1	<1	–	No	–	–	No
50‐59	M	NAFLD	CP‐B	Oxford‐AstraZeneca	1	1	–	No	–	–	No
40‐49	M	NAFLD	CP‐A	Oxford‐AstraZeneca	1	1	–	Yes	No	No	No
40‐49	M	Other	Noncirrhotic CLD	Pfizer‐BioNTech	1	2	–	No	–	–	No
60‐69	M	NAFLD	CP‐A	Oxford‐AstraZeneca	1	2	–	Yes	No	Yes	No
50‐59	F	NAFLD	CP‐A	Oxford‐AstraZeneca	1	3	–	Yes	No	No	No
60‐69	M	HBV	CP‐A	Oxford‐AstraZeneca	1	3	–	No	–	–	No
70‐79	M	Other	Noncirrhotic CLD	Pfizer‐BioNTech	1	3	–	No	–	–	No
60‐69	M	ALD	CP‐A	Moderna	1	4	–	No	–	–	No
50‐59	M	HCV	CP‐A	Bharat Biotech	1	4	–	No	–	–	No
50‐59	F	Other	CP‐A	CanSino	1	4	–	No	–	–	No
40‐49	F	Other	CP‐B	Oxford‐AstraZeneca	1	6	–	No	–	–	No
40‐49	M	ALD	CP‐B	Oxford‐AstraZeneca	1	8	–	Yes	No	No	No
70‐79	F	Other	CP‐B	Sinovac	2	5	1	No	–	–	No
50‐59	F	Other	CP‐C	Bharat Biotech	2	9	1	No	–	–	No
60‐69	M	HCV	CP‐A	Oxford‐AstraZeneca	2	9	2	Yes	No	No	No
60‐69	F	Other	CP‐B	Oxford‐AstraZeneca	2	6	3	No	–	–	No
50‐59	M	NAFLD	CP‐A	Pfizer‐BioNTech	2	9	3	No	–	–	No
70‐79	F	NAFLD	CP‐A	Pfizer‐BioNTech	2	9	6	Yes	No	No	No
60‐69	M	NAFLD	CP‐B	Oxford‐AstraZeneca	2	12	8	Yes	No	No	No
<40	M	Other	CP‐A	Oxford‐AstraZeneca	2	18	6	No	–	–	No

Full vaccinated patients in gray.

Abbreviations: ALD, alcohol‐associated liver disease; CP‐A, Child‐Pugh A; CP‐B, Child‐Pugh B; CP‐C, Child‐Pugh C; F, female; HBV, hepatitis B virus; HCV, hepatitis C virus; M, male; NAFLD, nonalcoholic fatty liver disease; v1, first vaccine dose; v2, second vaccine dose.